Detalles de la búsqueda
1.
Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.
Blood;
137(13): 1818-1827, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33150384
2.
Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
J Clin Immunol;
41(6): 1331-1338, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34036490
3.
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery.
Haemophilia;
27(3): e331-e339, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33772963
4.
Assessing goodness-of-fit for evaluation of dose-proportionality.
Pharm Stat;
20(2): 272-281, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33063443
5.
Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Haemophilia;
26(4): e168-e178, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32597029
6.
Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A.
Haemophilia;
26(3): 478-486, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338433
7.
Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Haemophilia;
25(5): 773-781, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31353761
8.
Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases.
Ann Allergy Asthma Immunol;
123(3): 271-279.e1, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31228628
9.
Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
Blood;
126(9): 1078-85, 2015 Aug 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-26157075
10.
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
J Clin Immunol;
36(6): 571-82, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27220317
11.
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
Blood;
122(5): 648-57, 2013 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23777763
12.
A hybrid method to estimate the minimum effective dose for monotone and non-monotone dose-response relationships.
Biometrics;
70(1): 103-9, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24571518
13.
Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.
Blood Adv;
2024 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38564770
14.
Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial.
J Thromb Haemost;
22(1): 90-100, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37717853
15.
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
J Allergy Clin Immunol;
130(4): 951-7.e11, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22846381
16.
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study.
Ther Adv Hematol;
14: 20406207231178596, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37465396
17.
Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
Expert Rev Hematol;
16(10): 793-801, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646148
18.
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases.
Immunotherapy;
14(4): 215-224, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34931880
19.
Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.
J Clin Immunol;
31(3): 323-31, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21424824
20.
Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
Clin Appl Thromb Hemost;
27: 1076029621989811, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33587652